Shots:

• Gilead has initiated two P-III studies assessing the safety and efficacy of its investigational therapy- Remdesivir in patients with moderate to severe COVID-19 in the UK
• The two studies have been granted UPHR status by the CMO and will initially involve 15 centers in the UK. Gilead is already evaluating the therapy in three ongoing clinical studies across China & the US
• Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity demonstrated both in vitro and in animal models against Marburg- MERS- SARS- and Ebola

Click here ­to­ read full press release/ article 

Ref: Pharrmiweb | Image: Gilead